论文部分内容阅读
肺癌在我国仍保持发病率及死亡率首位~[1]。其中非小细胞肺癌占肺癌总数的80%~85%~[2],而且30%~40%的患者诊断时已为局部晚期(AJCC分期为ⅢA~ⅢB期)。同期放化疗成为这部分患者的首选治疗手段~[3]。虽然现代放疗技术提高,但治疗效果仍然不理想,局部复发是肺癌放疗目前面临的最大困难。美国肿瘤放射治疗协会(Radiation Therapy Oncology Group,RTOG)关于肺癌同期放化疗的11个临床试验统计显示,局部等效
Lung cancer in China still maintain the incidence and mortality of the first ~ [1]. Non-small cell lung cancer accounts for 80% ~ 85% of the total number of lung cancer [2], and 30% ~ 40% of the patients have been diagnosed locally advanced (AJCC stage ⅢA ~ ⅢB). Radiotherapy during the same period has become the preferred treatment for this part of patients ~ 3. Although modern radiotherapy techniques improve, but the treatment effect is still not ideal, and local recurrence is the biggest difficulty in lung cancer radiotherapy. Statistics from 11 clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) on radiotherapy and chemotherapy of lung cancer show that the local equivalent